{"nctId":"NCT01732471","briefTitle":"Phase 3 Open-label Study to Evaluate the Response and Safety of Kuvan® in Subjects With Phenylketonuria","startDateStruct":{"date":"2012-11"},"conditions":["Phenylketonuria"],"count":90,"armGroups":[{"label":"Kuvan®","type":"EXPERIMENTAL","interventionNames":["Drug: Kuvan®"]}],"interventions":[{"name":"Kuvan®","otherNames":["Sapropterin dihydrochloride","6R-BH4 tetrahydrobiopterin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Willing and able to provide written informed consent (for children under 18 years old the parent\\[s\\]/guardians give informed consent, subjects 14-17 years old give additionally their own written informed consent)\n* Age of 4 - 18 years, inclusive\n* Confirmed clinical and biochemical hyperphenylalaninemia due to phenylketonuria documented by past medical history with at least 2 blood phenylalanine level greater than or equal to 400 micromole per liter obtained in 2 separate occasions\n* Blood phenylalanine level at screening greater than or equal to 450 micromole per liter (mean of two measurements)\n* For women of childbearing potential, a negative urine pregnancy test is required at screening and willingness to use a highly effective method of contraception is required while participating in the study\n* Subject and/or the parent/guardian willing and able to comply with study procedures\n* Subject and/or the parent/guardian willing to continue current diet unchanged during the 8 days response test and to adapt the diet according to phenylalanine therapeutic target range during the 6 week treatment period\n\nExclusion Criteria:\n\n* Subject already assessed for responsiveness to sapropterin dihydrochloride or other tetrahydrobiopterin (BH4)\n* Used any investigational agent other than Kuvan® (sapropterin dihydrochloride) within 30 days of screening, or required any investigational agent or vaccine prior to completion of all scheduled study assessments\n* Pregnant or breastfeeding, or considering pregnancy\n* Concurrent disease or conditions that would interfere with study participation or safety (for example, seizure disorder, asthma or other condition requiring oral or parenteral corticosteroid administration, insulin-dependent diabetes, or organ transplantation recipient)\n* Concurrent use of required concomitant treatment with any drug known to inhibit folate synthesis (for example, methotrexate), levodopa, phosphodiesterase type-5 (PDE-5) inhibitors (such as, sildenafil, vardenafil or tadalafil), medications that are known to affect nitric oxide synthesis metabolism or action\n* Any conditions, that, in the view of the Principal Investigator renders the subject at high risk for failure to comply with treatment or to complete the study\n* Clinical diagnosis of primary BH4 deficiency\n* Known hypersensitivity to Kuvan® (sapropterin dihydrochloride) or its excipients or to other approved or non-approved formulation of tetrabiopterin","healthyVolunteers":false,"sex":"ALL","minimumAge":"4 Years","maximumAge":"18 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Response to Kuvan® (Sapropterin Dihydrochloride) Treatment","description":"Response to Kuvan® (sapropterin dihydrochloride) treatment was defined as a reduction in blood phenylalanine levels of greater than or equal to 30% at Day 8 as compared to baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Blood Phenylalanine Levels at Day 8 in Overall Population","description":"Percent change in blood phenylalanine levels after 8-day Kuvan® therapy (response test period) was calculated as (blood phenylalanine level at Day 8 minus blood phenylalanine level at baseline)\\*100/ blood phenylalanine level at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.14","spread":"28.35"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Blood Phenylalanine Levels at Day 8 in Sub-population of Responders","description":"Percent change in blood phenylalanine levels after 8-day Kuvan® therapy (response test period) was calculated as (blood phenylalanine level at Day 8 minus blood phenylalanine level at baseline)\\*100/ blood phenylalanine level at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-44.25","spread":"15.13"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) in Overall Safety Population","description":"An adverse event (AE) was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":90},"commonTop":["Respiratory tract infection viral","Phenylketonuria","Respiratory tract infection","Retinal vascular disorder","Anaemia"]}}}